Exelixis Announces Settlement of Dispute with Genentech Regarding Companies ’ Collaboration

Effective July 1, 2017, as part of the settlement the companies entered into an amendment (the "Amendment") to the existing Collaboration Agreement, dated December 22, 2006, to revise the revenue and cost-sharing arrangements for the collaboration. The Amendment resolves the companies' dispute pursuant to the arbitration demand filed on June 3, 2016, and aligns both companies' interes ts in advancing cobimetinib as a promising therapy for patients with multiple forms of cancer.07/21/2017 (Source: Kidney Cancer Association)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader http://ift.tt/2uK1PIh
via IFTTT